Daniel Voss
Family Medicine · Georgetown, TXNPI 1639259625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 317 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,453 and has fallen 97.9% since, to $31 in 2025.
Across 317 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$777
- AbbVie$570
- Amarin Pharma, Inc.$396
- GSK$347
- Amgen$337
- Boehringer Ingelheim$294
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,656100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $777 |
| AbbVie(2 entities) | 38 | $570 |
| Amarin Pharma, Inc. | 26 | $396 |
| GSK | 27 | $347 |
| Amgen(2 entities) | 25 | $337 |
| Boehringer Ingelheim | 23 | $294 |
| Abbott | 12 | $261 |
| Lilly USA, LLC | 18 | $200 |
| AstraZeneca | 10 | $130 |
| Esperion Therapeutics, Inc. | 6 | $115 |
| Astellas Pharma US Inc | 6 | $109 |
| Mylan Specialty L.p. | 5 | $100 |
| Biohaven Pharmaceuticals, Inc. | 4 | $85 |
| Pfizer | 5 | $82 |
| Novartis | 5 | $78 |
| Merck | 6 | $76 |
| Johnson & Johnson | 6 | $74 |
| Medtronic(2 entities) | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Genentech USA, Inc. | 3 | $51 |
| Arbor Pharmaceuticals, Inc. | 3 | $39 |
| Ironshore Pharmaceuticals Inc. | 2 | $37 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Clarus Therapeutics Inc. | 1 | $23 |
| Bayer | 1 | $23 |
| Antares Pharma, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Bausch Health US, LLC | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
How this compares
$4,663 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Georgetown
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.